Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: J Invest Dermatol. 2009 May 21;129(10):2411–2418. doi: 10.1038/jid.2009.112

Table 2.

Systemic Therapies Received by Patients with Severe Psoriasis (n= 3603)*

Systemic Therapy Number of Patients with Severe Psoriasis (%)

Methotrexate 2114 (58.7%)
Psoralen 607 (16.9%)
Azathioprine 582 (16.2%)
Cyclosporine 390 (10.8%)
Etretinate or acetretin 333 (9.2%)
Hydroxyurea 208 (5.8%)
Mycophenolate mofetil 9 (0.3%)
*

Percentages do not add up to 100 because patients could have received more than 1 systemic therapy